Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046749 | 0.94 | CD69 (0.59) | CD69ELANESMN1; SMN2CYP2C19RXRA | |
| SCHEMBL26783094 | 0.86 | ESR1 (0.39) | CD69ELANECYP2C19ALDH1A1HPGD | |
| SCHEMBL26783100 | 0.86 | ESR1 (0.39) | CD69ELANECYP2C19ALDH1A1HPGD | |
| SCHEMBL15479693 | 0.82 | BCHE (0.43) | CD69ELANEALDH1A1PTGDR2HPGD | |
| SCHEMBL16501740 | 0.81 | CD69 (0.54) | CD69ELANESMN1; SMN2CYP2C19RXRA | |
| SCHEMBL14213234 | 0.80 | LMNA (0.36) | CD69ELANEALDH1A1HPGD | |
| SCHEMBL13992501 | 0.80 | ESR1 (0.42) | CD69ELANECYP2C19ALDH1A1HSD17B10 | |
| SCHEMBL14213236 | 0.79 | TSHR (0.38) | CD69ELANEALDH1A1HPGD | |
| SCHEMBL26783079 | 0.76 | BCHE (0.39) | CD69ELANECYP2C19ALDH1A1PPARA | |
| SCHEMBL7794927 | 0.75 | RXRA (0.50) | CD69ELANESMN1; SMN2CYP2C19RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716343-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-05-06 | — | — | US | disclosed |
| US-8642656-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | CLSPN, BID, CALU | CD69 3646/4885ELANE 141/4885SMN1; SMN2 4378/4885 |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | CLSPN, BID, CALU | CD69 3646/4885ELANE 141/4885SMN1; SMN2 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.